BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7558587)

  • 1. Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity.
    Groot K; Horvàth JE; Cai RZ; Schally AV
    Int J Pept Protein Res; 1995 Jun; 45(6):561-6. PubMed ID: 7558587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
    Pinski J; Yano T; Groot K; Cai RZ; Radulovic S; Schally AV
    Am J Physiol; 1992 Oct; 263(4 Pt 1):E712-7. PubMed ID: 1415689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration.
    Pinski J; Yano T; Rekasi Z; Cai RZ; Radulovic S; Schally AV
    Regul Pept; 1992 Oct; 41(3):185-93. PubMed ID: 1438988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.
    Radulovic S; Cai RZ; Serfozo P; Groot K; Redding TW; Pinski J; Schally AV
    Int J Pept Protein Res; 1991 Dec; 38(6):593-600. PubMed ID: 1726427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi.
    Cai RZ; Radulovic S; Pinski J; Nagy A; Redding TW; Olsen DB; Schally AV
    Peptides; 1992; 13(2):267-71. PubMed ID: 1409006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S; Schally AV; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
    Acta Oncol; 1994; 33(6):693-701. PubMed ID: 7946450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
    Qin Y; Halmos G; Cai RZ; Szoke B; Ertl T; Schally AV
    J Cancer Res Clin Oncol; 1994; 120(9):519-28. PubMed ID: 8045917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP.
    Qin Y; Ertl T; Cai RZ; Horvàth JE; Groot K; Schally AV
    Int J Cancer; 1995 Oct; 63(2):257-62. PubMed ID: 7591214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
    Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intracerebral ventricular administration of gastrin-releasing peptide and its receptor antagonist RC-3095 on learned fear responses in the rat.
    Merali Z; Mountney C; Kent P; Anisman H
    Behav Brain Res; 2011 Jan; 216(2):519-24. PubMed ID: 20801162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
    Narayan S; Spindel ER; Rubin NH; Singh P
    Cell Growth Differ; 1992 Feb; 3(2):111-8. PubMed ID: 1323998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.
    Schwartsmann G; DiLeone LP; Horowitz M; Schunemann D; Cancella A; Pereira AS; Richter M; Souza F; da Rocha AB; Souza FH; Pohlmann P; De Nucci G
    Invest New Drugs; 2006 Sep; 24(5):403-12. PubMed ID: 16505950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.